Engineered immune cells take on Hard-to-Treat liver cancer
NCT ID NCT07500220
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment for adults with advanced liver cancer that cannot be removed by surgery or has spread. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins found on liver cancer cells. Participants first receive chemotherapy to prepare their immune system, then the engineered cells are given by IV. The goal is to see if the treatment is safe and can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dual-target CAR-NK cells (engineered immune cells) plus chemotherapy
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced liver cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply to everyone. The treatment involves chemotherapy and engineered cells, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo aims to outperform standard care in advanced liver cancer
- Immunotherapy combo aims to shrink advanced liver tumors
- Engineered immune cells take aim at childhood liver cancers
- New study aims to find best first immunotherapy for advanced liver cancer
- Experimental combo aims to tackle advanced liver cancer
- New immunotherapy combo takes on advanced liver cancer